DR. STEVE W LOOYSEN O.D.
Prescription History 1285725820
Optometrist in Jamestown, ND

NPI Status: Active since September 27, 2006

Contact Information

821 1ST AVE S
JAMESTOWN, ND
ZIP 58401
Phone: (701) 252-3937
Fax: (701) 952-3937

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. STEVE W LOOYSEN O.D., an active Optometrist specialist practicing in Jamestown, ND. Our medical registry currently tracks 10 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 397 documented patient claims. Among these therapy options, the most frequently utilized medication is Timolol Maleate, which accounts for 99 claims alone.


Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Optometry
Provider Metrics Summary
Total Claims 31
30-Day Fills 58.9
Days Supply 1,681
ND State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills56.8
Peer Average Days Supply1,617
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $213.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.89

State Avg Cost Per Claim

$42.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Combigan

Generic Formulation: Brimonidine Tartrate/TimololSpecialty: Optometry
Provider Metrics Summary
Total Claims 17
30-Day Fills 23.3
Days Supply 612
ND State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills49.2
Peer Average Days Supply1,352
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.4% less volume than the regional standard for practitioners inside ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,739.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$396.42

State Avg Cost Per Claim

$315.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.

Therapeutic Applications

This combination medication is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This product contains brimonidine and timolol. These medications are used together when 1 drug is not controlling the pressure inside the eye. Brimonidine works by allowing better fluid drainage from within the eye and also by decreasing the amount of fluid formed in the eye. It belongs to a class of drugs known as alpha agonists. Timolol is thought to work by decreasing the amount of fluid formed in the eye. Timolol belongs to a class of drugs known as beta blockers. This medication is not recommended for use in children less than 2 years old due to an increased risk of serious side effects. Ask the doctor or pharmacist for more details.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Optometry
Provider Metrics Summary
Total Claims 11
30-Day Fills 23.7
Days Supply 710
ND State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills93.3
Peer Average Days Supply2,791
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.6% less volume than the regional standard for practitioners inside ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $57.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.19

State Avg Cost Per Claim

$25.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Fluorometholone

Generic Formulation: FluorometholoneSpecialty: Optometry
Provider Metrics Summary
Total Claims 23
30-Day Fills 39.5
Days Supply 1,077
ND State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills56.3
Peer Average Days Supply1,526
Conservative Utilization

This provider writes prescriptions for this formulation 36.1% less frequently than the standard regional baseline metric for practitioners inside ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,306.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$100.28

State Avg Cost Per Claim

$90.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Fluorometholone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 89
30-Day Fills 137.7
Days Supply 3,657
ND State Average Benchmarks
Peer Average Claims108.0
Peer Average 30-Day Fills165.7
Peer Average Days Supply4,549
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,175.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.20

State Avg Cost Per Claim

$16.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Lumigan

Generic Formulation: BimatoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 68
30-Day Fills 80.2
Days Supply 2,027
ND State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills54.6
Peer Average Days Supply1,500
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 83.8% higher than the standard regional baseline profile for ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,427.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$315.12

State Avg Cost Per Claim

$390.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Rhopressa

Generic Formulation: Netarsudil MesylateSpecialty: Optometry
Provider Metrics Summary
Total Claims 18
30-Day Fills 21.4
Days Supply 503
ND State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills42.1
Peer Average Days Supply1,069
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,841.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$324.51

State Avg Cost Per Claim

$348.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Netarsudil is used to treat high pressure inside the eye due to certain eye conditions (such as open-angle glaucoma, ocular hypertension). This medication is thought to work by increasing the flow of fluid out of the eye. This helps lower pressure inside the eye. Lowering high pressure inside the eye can help prevent loss of vision or blindness.

Simbrinza

Generic Formulation: Brinzolamide/Brimonidine TartSpecialty: Optometry
Provider Metrics Summary
Total Claims 21
30-Day Fills 23.3
Days Supply 700
ND State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills30.0
Peer Average Days Supply893
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,621.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$220.05

State Avg Cost Per Claim

$209.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two medications used to treat high pressure in the eye due to glaucoma (open-angle glaucoma-type) or a certain other eye disease (ocular hypertension). Lowering high pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This product contains brinzolamide and brimonidine. These two medications work together to decrease the amount of fluid within the eye. Brinzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors. Brimonidine belongs to a class of drugs known as alpha agonists. This product is not recommended for use in children younger than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Optometry
Provider Metrics Summary
Total Claims 99
30-Day Fills 146.1
Days Supply 4,105
ND State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills114.6
Peer Average Days Supply3,355
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 62.3% higher than the standard regional baseline profile for ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,647.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.64

State Avg Cost Per Claim

$15.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Tobramycin-Dexamethasone

Generic Formulation: Tobramycin/DexamethasoneSpecialty: Optometry
Provider Metrics Summary
Total Claims 20
30-Day Fills 21.3
Days Supply 303
ND State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills30.9
Peer Average Days Supply561
Conservative Utilization

This provider writes prescriptions for this formulation 31.0% less frequently than the standard regional baseline metric for practitioners inside ND. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,718.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$85.93

State Avg Cost Per Claim

$86.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A topical preparation of tobramycin and dexamethasone that is used for treating or preventing superficial bacterial infections of the eye.

Therapeutic Applications

This medication is used to treat or prevent eye infections. This medication contains two drugs. Tobramycin belongs to a class of drugs called aminoglycoside antibiotics. It works by stopping the growth of bacteria. Dexamethasone belongs to a class of drugs called corticosteroids. It works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. STEVE W LOOYSEN O.D. provides transparency into local medical care patterns within Jamestown, ND.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.